Serial quantification of procalcitonin (PCT) predicts clinical outcome and prognosis in patients with community-acquired pneumonia (CAP)

Journal of Infection and Chemotherapy

Volumn 20, Issue 2, 2014, Pages 97-103

  Tamura, Masaki ^a   Watanabe, Masato ^a   Nakajima, Akira ^a   Kurai, Daisuke ^a   Ishii, Haruyuki ^a   Takata, Saori ^a   Nakamoto, Keitaro ^a   Sohara, Erei ^a   Honda, Koujirou ^a   Nakamura, Masuo ^a   Inui, Toshiya ^a   Wada, Hiroo ^a   Takizawa, Hajime ^a   Goto, Hajime ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Community acquired pneumonia (CAP); Procalcitonin (PCT)

Indexed keywords

PROCALCITONIN;

ADULT; AGED; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

BIOMARKER; COMMUNITY-ACQUIRED PNEUMONIA (CAP); PROCALCITONIN (PCT);

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; TREATMENT OUTCOME;

EID: 84903707885     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2013.09.005     Document Type: Conference Paper

References (21)

1. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993;341:515-8 (Pubitemid 23066085)
2. Linscheid P, Seboek D, Nylen ES, Langer I, Schlatter M, Becker KL, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: A novel product of human adipose tissue. Endocrinology 2003;144:5578-84 (Pubitemid 37476087)
3. Wrenger S, Kahne T, Bohuon C, Weglohner W, Ansorge S, Reinhold D. Aminoterminal truncation of procalcitonin, a marker for systemic bacterial infections, by dipeptidyl peptidase IV (DP IV). FEBS Lett 2000;466:155-9 (Pubitemid 30050703)
4. Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001;86:396-404 (Pubitemid 32109825)
5. Nijsten MW, Olinga P, The TH, de Vries EG, Koops HS, Groothuis GM, et al. Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med 2000;28:458-61 (Pubitemid 30120889)
6. Linscheid P, Seboek D, Schaer DJ, Zulewski H, Keller U, Muller B. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004;32:1715-21 (Pubitemid 39050523)
7. Balog A, Ocsovszki I, Mandi Y. Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes. Immunol Lett 2002;84: 199e203 (Pubitemid 35292379)
8. Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 2008;52. 48-58 e2
9. Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 2008;31:349e55
10. The Committee for the Guidelines in Management of Respiratory Infection JRS. The Japanese Respiratory Society guidelines for the management of community-acquired pneumonia in adults. The Japanese Respiratory Society; 2005
11. Nursing and healthcare-associated pneumonia. The Japanese Respiratory Society; 2011
12. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243e50 (Pubitemid 27044625)
13. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;(44 Suppl. 2):S27-72 (Pubitemid 46290553)
14. Dandona P, Nix D, Wilson MF, Aljada A, Love J, Assicot M, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994;79:1605-8
15. Morgenthaler NG, Struck J, Chancerelle Y, Weglohner W, Agay D, Bohuon C, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. Horm Metab Res 2003;35:290-5 (Pubitemid 37011514)
16. Preas 2nd HL, Nylen ES, Snider RH, Becker KL, White JC, Agosti JM, et al. Effects of anti-inflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia. J Infect Dis 2001;184:373e6 (Pubitemid 32662188)
17. Wiedermann FJ, Kaneider N, Egger P, Tiefenthaler W, Wiedermann CJ, Lindner KH, et al. Migration of human monocytes in response to procalcitonin. Crit Care Med 2002;30:1112-7 (Pubitemid 34508036)
18. Hoffmann G, Czechowski M, Schloesser M, Schobersberger W. Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med 2002;30:2091-5
19. Nylen ES, Whang KT, Snider Jr RH, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998;26:1001-6 (Pubitemid 28272848)
20. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J 2011;37:384-92
21. Menendez R, Sahuquillo-Arce JM, Reyes S, Martinez R, Polverino E, Cilloniz C, et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest 2012;141: 1537-45.